Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 7/20 | 0.72 |
| ▸ | DRD4 | P21917 | 6/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038574 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL31038578 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL3404095 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL8160207 | 0.89 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL10865110 | 0.86 | HTR1A (0.75) | DRD2HTR1AHTR2AHTR2BSLC6A4 | |
| SCHEMBL4249939 | 0.85 | DRD2 (0.74) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL8032044 | 0.85 | DRD2 (0.74) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL4259307 | 0.85 | DRD2 (0.73) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL18479118 | 0.85 | DRD2 (0.73) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL4258649 | 0.84 | DRD2 (0.72) | DRD2HTR1AHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3244897-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | Reviva Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2016115144-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS INC. (US) | 2016-07-21 | — | — | WO | claimed |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | REVIVA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3244896-B1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-107206007-B | Method for treating pulmonary hypertension | 雷维瓦药品公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS INC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3749324-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | Reviva Pharmaceuticals Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-111770755-A | Methods of treating pulmonary fibrosis | 雷维瓦药品公司 | 2020-10-13 | — | — | CN | disclosed |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2015-01-01 | — | — | US | disclosed |
| US-8859552-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461154-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8431570-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-8188076-B2 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | DRD2 380/4885HTR1A 39/4885HTR2A 18/4885 |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, HTR2A | DRD2 10/4885HTR1A 32/4885HTR2A 3/4885 |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | DRD2 18/4885HTR1A 33/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.